Abstract

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disease usually presenting after infection. Emerging evidence supports that energy metabolism is affected in ME/CFS, but a unifying metabolic phenotype has not been firmly established. We performed global metabolomics, lipidomics, and hormone measurements, and we used exploratory data analyses to compare serum from 83 patients with ME/CFS and 35 healthy controls. Some changes were common in the patient group, and these were compatible with effects of elevated energy strain and altered utilization of fatty acids and amino acids as catabolic fuels. In addition, a set of heterogeneous effects reflected specific changes in 3 subsets of patients, and 2 of these expressed characteristic contexts of deregulated energy metabolism. The biological relevance of these metabolic phenotypes (metabotypes) was supported by clinical data and independent blood analyses. In summary, we report a map of common and context-dependent metabolic changes in ME/CFS, and some of them presented possible associations with clinical patient profiles. We suggest that elevated energy strain may result from exertion-triggered tissue hypoxia and lead to systemic metabolic adaptation and compensation. Through various mechanisms, such metabolic dysfunction represents a likely mediator of key symptoms in ME/CFS and possibly a target for supportive intervention.

Highlights

  • Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) typically presents with a sudden onset following an infection

  • We previously found indications that obstructed pyruvate flux through the central mitochondrial enzyme pyruvate dehydrogenase (PDH) plays a role in ME/CFS [15], and this is supported by other studies reporting changes in amino acid and tricarboxylic acid (TCA) metabolites [27,28,29, 44]

  • Several of the findings agree with altered utilization of amino acids in patients with ME/CFS, including branched chain amino acids (BCAAs), tryptophan, and others

Read more

Summary

Introduction

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) typically presents with a sudden onset following an infection. ME/CFS affects multiple organ systems, and additional symptoms include unrefreshing sleep, cognitive problems (referred to as brain fog), autonomic dysfunction, sensory hypersensitivity, and widespread pain [1, 2]. Using the Canadian consensus criteria [1], the prevalence of ME/CFS is 0.1%–0.8% in both adults and children [3,4,5]. Patients recovering from SARS-CoV-2 infection (COVID-19) may develop ME/CFS-like illness While the etiology of ME/CFS is still unknown, accumulating evidence documents measurable biological changes in the blood of patients with ME/CFS. A deeper understanding of the underlying biological mechanisms is urgently required to meet this major health challenge

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call